Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.…
Oramed: Q3 Earnings Snapshot
Oramed Pharmaceuticals (NASDAQ: ORMP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 3.570 USD on 20 November 2026, up 74.1% over 52 weeks. Its 52-week range is 2.090 USD to 5.430 USD: the price is 34.3% below the high and 70.8% above the low.
At a market capitalisation of 155.24M USD, it trades at 1.0 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 97% for ORMP. It pays a dividend yielding 6.78% (it pays out 7% of its earnings), against a median of 0.95% among the dividend payers in that peer group.
Oramed Pharmaceuticals reports return on equity of 32.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 52.24M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 7.000 USD is 96.1% above the current price. The next earnings report is expected on 25 March 2027.